- Accesswire•2 days ago
TORONTO, ON / ACCESSWIRE / October 25, 2016 / Theralase Technologies Inc. (" Theralase® " or the " Company ") ( TLT:TSX-V ) ( TLTFF:OTC ), a leading biotech company focused on the commercialization ...
- Zacks Small Cap Research•8 days ago
The National Cancer Institute (NCI) estimates that Glioblastoma Multiforme (GBM), a form of malignant brain tumor made up of star-shaped cells, accounts for 52% of all primary brain tumors and occurs primarily in adults between the ages of 45 and 70. It has poor prognosis, remains refractory to current treatment and had a mortality rate of 67% in 2015.
Theralase Technologies Inc. (TLT.V)
TSXV - TSXV Delayed Price. Currency in CAD
|Day's Range||0.38 - 0.40|
|52wk Range||0.27 - 0.46|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-7.96|
|Avg Vol (3m)||261,215|
|Dividend & Yield||N/A (N/A)|